2024
A kalihinol analog disrupts apicoplast function and vesicular trafficking in P. falciparum malaria
Chahine Z, Abel S, Hollin T, Barnes G, Chung J, Daub M, Renard I, Choi J, Vydyam P, Pal A, Alba-Argomaniz M, Banks C, Kirkwood J, Saraf A, Camino I, Castaneda P, Cuevas M, De Mercado-Arnanz J, Fernandez-Alvaro E, Garcia-Perez A, Ibarz N, Viera-Morilla S, Prudhomme J, Joyner C, Bei A, Florens L, Ben Mamoun C, Vanderwal C, Le Roch K. A kalihinol analog disrupts apicoplast function and vesicular trafficking in P. falciparum malaria. Science 2024, 385: eadm7966. PMID: 39325875, DOI: 10.1126/science.adm7966.Peer-Reviewed Original ResearchConceptsP. falciparum malariaHumanized mouse modelPlasmodium falciparum</i> strainsIn vivo studiesParasite apicoplastDrug sensitivityTherapeutic profileVesicular traffickingGenomic analysisLipid biogenesisSecretory machineryAsexual replicationGenetic analysisReduced susceptibilityCellular traffickingApicoplast functionStrong efficacyMED6Sexual differentiationHemolytic activityDrug pipelineApicoplastKalihinolTraffickingMalariaTwo decades of molecular surveillance in Senegal reveal rapid changes in known drug resistance mutations over time
Ndiaye Y, Wong W, Thwing J, Schaffner S, Brenneman K, Tine A, Diallo M, Deme A, Sy M, Bei A, Thiaw A, Daniels R, Ndiaye T, Gaye A, Ndiaye I, Toure M, Gadiaga N, Sene A, Sow D, Garba M, Yade M, Dieye B, Diongue K, Zoumarou D, Ndiaye A, Gomis J, Fall F, Ndiop M, Diallo I, Sene D, Macinnis B, Seck M, Ndiaye M, Ngom B, Diedhiou Y, Mbaye A, Ndiaye L, Sy N, Badiane A, Hartl D, Wirth D, Volkman S, Ndiaye D. Two decades of molecular surveillance in Senegal reveal rapid changes in known drug resistance mutations over time. Malaria Journal 2024, 23: 205. PMID: 38982475, PMCID: PMC11234717, DOI: 10.1186/s12936-024-05024-8.Peer-Reviewed Original ResearchConceptsPfcrt K76TArtemisinin-based combination therapyPfdhps A437GSeasonal malaria chemopreventionK76TDrug resistance mutationsMolecular surveillanceA437GSulfadoxine-pyrimethamineArtesunate-amodiaquineSingle nucleotide polymorphismsDrug resistance markersResistance mutationsEfficacy of artesunate-amodiaquineWithdrawal of chloroquineMalaria control effortsP. falciparum parasitesResistance markersCombination of single nucleotide polymorphismsParasite drug resistanceWhole-genome sequencingAQ resistanceHaplotype-based analysisMalaria chemopreventionCombination therapy
2023
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
Yade M, Dièye B, Coppée R, Mbaye A, Diallo M, Diongue K, Bailly J, Mama A, Fall A, Thiaw A, Ndiaye I, Ndiaye T, Gaye A, Tine A, Diédhiou Y, Mbaye A, Doderer-Lang C, Garba M, Bei A, Ménard D, Ndiaye D. Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017. Malaria Journal 2023, 22: 167. PMID: 37237307, PMCID: PMC10223908, DOI: 10.1186/s12936-023-04588-1.Peer-Reviewed Original ResearchConceptsRing-stage survival assayART resistancePlasmodium falciparum isolatesMost malaria deathsLong-term useCurative treatmentCombination therapyMalaria deathsMinor variantsFalciparum isolatesPfkelch13 geneSurvival assaysParasite susceptibilityResultsAll samplesPfKelch13Spread of parasitesSaharan AfricaExMain determinantsIsolatesTherapySusceptibilityDeep sequencing approachTracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial section
2015
The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity
Tubman VN, Mejia P, Shmukler BE, Bei AK, Alper SL, Mitchell JR, Brugnara C, Duraisingh MT. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity. Antimicrobial Agents And Chemotherapy 2015, 60: 613-616. PMID: 26459896, PMCID: PMC4704178, DOI: 10.1128/aac.01668-15.Peer-Reviewed Original ResearchConceptsGardos channel inhibitorChannel inhibitorsSickle cell diseaseC57BL/6 miceClinical trialsCell diseaseAntimalarial developmentPlasmodium growthErythrocyte dehydrationGardos channelSenicapocBlood stagesBiochemical profileAntimalarial activityPrimate plasmodiaVitro growthInhibitorsPatientsParasitemiaBlockadeDiseaseMiceTrials